Phaseline

Companies › DeuterOncology

DeuterOncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DO-2
Deuterated MET kinase inhibitor
METPhase 1Adult Solid TumorSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05752552DO-2Phase 1Adult Solid TumorOncologySep 2027

Targets

MET (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Beijing Scitech-Mq Pharmaceuticals IDEAYA Biosciences Shanghai Henlius Biotech Pierre Fabre Medicament

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.